- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04284839
Essai sur l'anticoagulation orale directe par rapport à la warfarine après chirurgie cardiaque (DANCE)
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.
Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.
In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.
The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.
A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Richard Whitlock, MD, PhD
- Numéro de téléphone: 40306 905-527-4322
- E-mail: richard.whitlock@phri.ca
Sauvegarde des contacts de l'étude
- Nom: Emilie Belley-Cote, MD, MSc
- Numéro de téléphone: 40306 905-527-4322
- E-mail: emilie.belley-cote@phri.ca
Lieux d'étude
-
-
-
Bonn, Allemagne, 53127
- Actif, ne recrute pas
- University Hospital Bonn Heart Center
-
Essen, Allemagne, 45147
- Pas encore de recrutement
- West-German Heart and Vascular Center, University of Duisburg-Essen
-
Contact:
- Matthias Thielmann, MD, PhD
-
Chercheur principal:
- Matthias Thielmann, MD, PhD
-
Hamburg, Allemagne, 20246
- Recrutement
- University Medical Center Hamburg-Eppendorf
-
Contact:
- Simon Pecha, MD
-
Chercheur principal:
- Simon Pecha, MD
-
-
Saxony
-
Leipzig, Saxony, Allemagne, 04289
- Actif, ne recrute pas
- Heart Center Leipzig
-
-
Thuringia
-
Jena, Thuringia, Allemagne, Germany
- Recrutement
- University Hospital Jena
-
Contact:
- Torsten Doenst, MD, PhD
-
Chercheur principal:
- Torsten Doenst, MD, PhD
-
-
-
-
Victoria
-
Fitzroy, Victoria, Australie, 3065
- Recrutement
- St Vincent's Hospital Melbourne
-
Contact:
- Andrew Newcomb, MD
-
Chercheur principal:
- Andrew Newcomb, MD
-
Parkville, Victoria, Australie, 3050
- Pas encore de recrutement
- Royal Melbourne Hospital, University of Melbourne
-
Contact:
- Alistair Royse, MD
-
Chercheur principal:
- Alistair Royse, MD
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2C8
- Recrutement
- University of Alberta Hospital
-
Chercheur principal:
- Steven Meyer, MD
-
Contact:
- Steven Meyer, MD
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Recrutement
- University of British Columbia
-
Chercheur principal:
- Erica Wang, PharmD
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R2H 2A6
- Recrutement
- St. Boniface Hospital
-
Chercheur principal:
- Michael Yamashita, MD
-
Contact:
- Michael Yamashita, MD
-
-
New Brunswick
-
Saint John, New Brunswick, Canada, E2L4L2
- Actif, ne recrute pas
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Recrutement
- Health Science Centre
-
Chercheur principal:
- Hasib Hanif, MD
-
-
Ontario
-
Greater Sudbury, Ontario, Canada, P3E 5J1
- Recrutement
- Health Sciences North Research Institute
-
Chercheur principal:
- Bindu Bittira, MD
-
Hamilton, Ontario, Canada, L8L 2X2
- Recrutement
- Hamilton General Hospital
-
Contact:
- Emilie Belley-Cote, MD, MSc
- Numéro de téléphone: 40306 905-527-4322
- E-mail: emilie.belley-cote@phri.ca
-
Toronto, Ontario, Canada, M5G 2C4
- Recrutement
- Toronto General Hospital
-
Contact:
- Vivek Rao, MD
-
Chercheur principal:
- Vivek Rao, MD
-
Toronto, Ontario, Canada, M4N 3M5
- Recrutement
- Sunnybrook Hospital
-
Contact:
- Stephen Fremes, MD
-
Chercheur principal:
- Stephen Fremes, MD
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Recrutement
- Montreal Heart Institute
-
Contact:
- Philippe Demers, MD
-
Chercheur principal:
- Philippe Demers, MD
-
Montreal, Quebec, Canada, H4J1C5
- Recrutement
- Hôpital Sacré-Coeur de Montréal
-
Chercheur principal:
- Hugues Jeanmart, MD
-
Contact:
- Hugues Jeanmart, MD
-
Québec, Quebec, Canada, G1V 4G5
- Recrutement
- IUCPQ-ULaval
-
Contact:
- Eric Dumont, MD
-
Chercheur principal:
- Eric Dumont, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥18 years at the time of enrolment,
- Open heart surgery in the last 10 days,
- Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
- Informed consent from either the patient or a substitute decision-maker.
Exclusion Criteria:
- Mechanical valve replacement,
- Antiphospholipid syndrome (triple positive),
- Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
- Known significant liver disease (Child-Pugh classification B and C),
- Left ventricular thrombus,
- Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
- Known contraindication for any DOAC or VKA,
- Women who are pregnant, breastfeeding, or of childbearing potential,
- Surgery including left ventricular assist device implantation or cardiac transplantation,
- Previously enrolled in this trial,
- Follow-up not possible,
- History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation factorielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Direct Oral Anticoagulation (DOAC)
Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician. |
Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
Autres noms:
|
|
Comparateur placebo: Vitamin K Antagonist
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range. |
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Major Bleeding
Délai: 30-Days post-randomization
|
Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis) |
30-Days post-randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Composite d'accident vasculaire cérébral et d'embolie artérielle systémique non centrale du système nerveux à 30 et 90 jours.
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
Saignement majeur
Délai: 90 jours post-randomisation
|
90 jours post-randomisation
|
|
Épanchement pleural ou péricardique nécessitant un drainage
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
Embolie artérielle systémique
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
AVC ischémique
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
Thrombose veineuse profonde
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
Embolie pulmonaire
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
Durée du séjour hospitalier post-opératoire
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
Mortalité toutes causes confondues
Délai: 6 mois après la randomisation
|
6 mois après la randomisation
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Infarctus du myocarde
Délai: 30 jours et 90 jours post-randomisation
|
30 jours et 90 jours post-randomisation
|
|
|
Association entre thrombose valvulaire infraclinique et thrombose valvulaire aortique cliniquement significative, accident vasculaire cérébral ou embolie systémique
Délai: 90 jours
|
90 jours
|
|
|
Minor Bleeding
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All bleeding (major plus minor)
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Valve Thrombosis
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Hemorrhagic stroke
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Stroke
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Arterial Thrombosis/thromboembolism
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis |
30-Days and 90-Days post-randomization
|
|
Quality of Life - EQ-5D-5L
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Measured by The EQ-5D-5L Questionnaire |
30-Days and 90-Days post-randomization
|
|
Patient Satisfaction with Anticoagulant treatment
Délai: 30-Days and 90-Days post-randomization
|
Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire |
30-Days and 90-Days post-randomization
|
|
Subclinical Valve Thrombosis on CT scan
Délai: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Mean Aortic Valve g=Gradient on echocardiogram
Délai: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Aortic Valve Reintervention
Délai: 60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Emilie Belley-Cote, MD, MSc, McMaster University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Conditions pathologiques, signes et symptômes
- Hémorragie
- Composés de soufre
- Produits chimiques organiques
- Pyridines
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Benzimidazoles
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Pyrans
- Morpholines
- Oxazines
- Thiophenes
- Coumarines
- Benzopyrans
- 4-hydroxycoumarines
- Rivaroxaban
- Dabigatran
- Warfarine
- apixaban
- édoxaban
Autres numéros d'identification d'étude
- DANCE-2020
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .